Clinical Trials Logo

Filter by:
NCT ID: NCT06128603 Recruiting - Clinical trials for Laparoscopic Pancreaticoduodenectomy

Analysis of Intraoperative Bleeding Characteristics in Laparoscopic Pancreaticoduodenectomy

Start date: October 1, 2023
Phase:
Study type: Observational

In this study, we analyze the common bleeding characteristics in laparoscopic pancreaticoduodenectomy by reviewing and annotating bleeding information from previous surgical videos as well as surgical operation OSATS technique scores. From there, we reflect on the correlation between surgical operating technique and intraoperative bleeding, as well as on the correlation between intraoperative bleeding and short-term postoperative outcomes.

NCT ID: NCT06128577 Completed - Sarcopenia Clinical Trials

Bioindicators Associated With Sarcopenia Before and After Intensive Lifestyle Intervention

Start date: March 1, 2022
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to explore whether the bioindicators of body composition, nutrition-related indicators (lymphocytes, albumin), lipids, and thyroid hormones are associated with sarcopenia and the changes in these indicators after an intensive lifestyle intervention. The main questions it aims to answer are: - whether the bioindicators such as lymphocytes, albumin, lipids, thyroid hormones, fat mass, fat-free mass, and basal metabolic mass are associated with the development of sarcopenia. - the changes of these bioindicators that occur in older adults after going through an intensive intervention. Participants will receive a 3-month intensive intervention consisting of an intensive nutritional intervention and an individually designed exercise intervention. Nutritional and exercise prescriptions are co-designed through a nutritionist and rehabilitation physician. Researchers will compare bioindicators in the sarcopenia group before and after intensive lifestyle intervention to determine the association with sarcopenia.

NCT ID: NCT06128421 Recruiting - Malnutrition Clinical Trials

Individual Nutrition Support in HBV-ACLF Patients at Nutrition Risk

Start date: November 23, 2023
Phase: N/A
Study type: Interventional

This study aims to investigate the safety and efficacy of individual nutrition support for treating hepatitis b virus(HBV) related acute-on-chronic liver failure patients at nutrition risk

NCT ID: NCT06128252 Recruiting - Gastric Cancer Clinical Trials

Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

This project aims to evaluate the efficacy and safety of oral taurine supplementation combined with PD-1 inhibitor (serplulimab) and chemotherapy in inducing systemic CD8+ T cell responses and achieving improved gastric cancer patient outcomes than with serplulimab and chemotherapy alone.

NCT ID: NCT06128148 Recruiting - Lung Neoplasms Clinical Trials

Study of Oral JYP0322 in Patients With Locally Advanced or Metastatic Cancer Targeting ROS1 Molecular Fusion.

Start date: May 4, 2022
Phase: Phase 1
Study type: Interventional

An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced/metastatic solid tumors .

NCT ID: NCT06127927 Recruiting - Cardiogenic Shock Clinical Trials

Evaluation the Efficacy and Safety of an Interventional Left Ventricular Assist System for Hemodynamic Support in Patients With Cardiogenic Shock

Start date: November 8, 2023
Phase: N/A
Study type: Interventional

Imported Impella The price is relatively expensive and difficult for ordinary patients to afford. In order to better meet the growing clinical needs in China, Anhui Tongling Bionic Technology Co., Ltd. has developed an interventional left ventricular assist system. The test device was tested in preclinical animals It has shown good effectiveness and safety. Through the implementation of this clinical trial, the interventional left ventricular assist system The safety and effectiveness of the system for hemodynamic support in patients with cardiogenic shock have led to further development of this product in the country.

NCT ID: NCT06127875 Recruiting - Clinical trials for Stress, Psychological

Effects of Trying to Conceive Using an Home- or Hospital-based Ovulation Monitoring on Stress

Start date: November 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to compare the difference of stress level and anxiety and depression between couples under home ovulation monitoring and hospital ultrasound monitoring.And whether it has a negative effect on the couple's sexual behavior.The participants were all healthy couples with fertility requirements from the reproductive Center of the First Hospital of Jilin University.The main questions it aims to answer are: - [question1] : Does ultrasound monitoring of ovulation increase stress levels and anxiety and depression in couples trying to conceive? - [question2] : Does ovulation monitoring affect couples' sexual function and satisfaction? Participants will be asked to fill out questionnaires three times over four menstrual cycles.

NCT ID: NCT06127589 Recruiting - Smoking Cessation Clinical Trials

The "Quit-for-Kids" Project: to Increase Abstinence and Protect Children From Tobacco Smoke Exposure

Start date: February 5, 2024
Phase: N/A
Study type: Interventional

This project aims to test the effectiveness of an integrated intervention of brief cessation advice (AWARD), Nicotine Replacement Therapy, and Instant Messaging support compared with waitlist control participants among adult daily smokers who lived with their children and non-smoking partners.

NCT ID: NCT06127498 Recruiting - SARS-CoV-2 Clinical Trials

The Safety and Tolerability of A8G6 COVID-19 Neutralization Antibody Combined With Nasal Spray

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

This is a randomized, double-blind, placebo-parallel intervention clinical study that will include approximately 108 healthy subjects based on inclusion and exclusion criteria. Patients meeting inclusion and exclusion criteria were randomly assigned to one of four different cohorts. Subjects in each cohort were randomly assigned 5:1 to two parallel administration groups, one of which served as a control. Each cohort was given either the experimental drug or placebo by nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose. Right nostril and nasal swabs were collected for immunotoxicity, immunogenicity (immunogenicity collection and detection in cohorts 3 and 4 only), and drug concentration detection. Subjects in the first three cohort were required to return to the study Center 3±1 days after the last dose for blood samples, bilateral nostril and nasal swabs for drug concentration, immunotoxicity, physical examination, vital signs, and safety laboratory indicators (blood routine, blood biochemical, and urine routine). Subjects in cohort 4 returned to the study center 7±2 days after the last dose. To evaluate the safety and tolerability of A8G6 COVID-19 neutralization and antibody combined nasal spray in healthy subjects by comparing the test results of subjects in different cohorts, and to study its concentration in serum and nasal swabs in healthy subjects.

NCT ID: NCT06127433 Recruiting - Clinical trials for Insulin Pump,Continuous Glucose Monitoring Technology

The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes

Start date: March 7, 2023
Phase: Phase 4
Study type: Interventional

This study aims to explore the effectiveness and safety of the in-hospital-out-of-hospital synergistic short-term insulin intensive therapy model based on patch insulin pump and continuous glucose monitoring technology through a randomized controlled study, and evaluate the possibility of blood glucose parameters derived from continuous glucose technology in predicting long-term blood glucose remission, so as to provide important reference data for the precision, intelligence, and integrated improvement of short-term insulin intensive therapy.